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Treatment with G-CSF reduces acute 
myeloid leukemia blast viability in the presence 
of bone marrow stroma
Meritxell Nomdedeu1,2, María Carmen Lara‑Castillo1, Amaia Etxabe1, Josep María Cornet‑Masana1, 
Marta Pratcorona1,2,3,5, Marina Díaz‑Beyá1,2,3, Xavier Calvo4, María Rozman4, Dolors Costa4, Jordi Esteve1,2,3 
and Ruth M. Risueño1* 
Abstract 
Background: The resulting clinical impact of the combined use of G‑CSF with chemotherapy as a chemosensitizing 
strategy for treatment of acute myeloid leukemia (AML) patients is still controversial. In this study, the effect of ex vivo 
treatment with G‑CSF on AML primary blasts was studied.
Methods: Peripheral blood mononuclear cells from AML patients were treated with G‑CSF at increasing doses, alone 
or in co‑culture with HS‑5 stromal cells. Cell viability and surface phenotype was determined by flow cytometry 72 h 
after treatment. For clonogenicity assays, AML primary samples were treated for 18 h with G‑CSF at increasing con‑
centrations and cultured in methyl‑cellulose for 14 days. Colonies were counted based on cellularity and morphology 
criteria.
Results: The presence of G‑CSF reduced the overall viability of AML cells co‑cultured with bone marrow stroma; 
whereas, in absence of stroma, a negligible effect was observed. Moreover, clonogenic capacity of AML cells was 
significantly reduced upon treatment with G‑CSF. Interestingly, reduction in the AML clonogenic capacity correlated 
with the sensitivity to chemotherapy observed in vivo.
Conclusions: These ex vivo results would provide a biological basis to data available from studies showing a clinical 
benefit with the use of G‑CSF as a priming agent in patients with a chemosensitive AML and would support imple‑
mentation of further studies exploring new strategies of chemotherapy priming in AML.
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Background
According to the hierarchic model of cancer, AML cells 
are maintained by a subset of cells, called leukemic stem 
cells (LSCs), which have the capacity of self-renewal and 
differentiation [1]. Due to their stem cell–like properties, 
LSCs are the cell population showing a highest resist-
ance to conventional chemotherapeutic agents used 
in AML treatment, such as anthracyclines and cytara-
bine [2]. Additionally, chemotherapy resistance may be 
partially explained by the protective effect exerted by 
bone marrow niche on leukemia cells against virtually 
any type of therapy [3], and might contribute to the high 
incidence of relapse observed after frontline chemother-
apy [2]. Therefore, AML therapy requires the complete 
eradication of LSCs in order to achieve long-term cure. 
Administration of granulocyte colony-stimulating factor 
(G-CSF) concurrently with induction chemotherapy, as 
a priming strategy, has been used based on pre-clinical 
data suggesting a sensitization of LSCs to the cytotoxic 
effect of conventional chemotherapy with the concomi-
tant administration of G-CSF via differentiation induc-
tion, cell cycle entry stimulation, and mobilization from 
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the bone marrow [4]. Additionally, G-CSF could exert 
its anti-leukemic effect inducing mobilization out of the 
protective bone marrow microenvironment by disrupting 
the CXCR4-CXCL12 axis [5].
In clinics, the simultaneous administration of G-CSF 
and chemotherapy as a priming strategy has yielded 
conflicting results. Thus, some reports have described 
a favorable effect of G-CSF priming in favorable and 
the intermediate risk AML patients, without clinical 
benefit in patients with unfavorable cytogenetics [6, 7].
In contrast, other studies have failed to show a clinical 
effect of priming strategies, although these conflicting 
results must be due in part to different patient inclu-
sion criteria, disease status and treatment administered 
[8, 9].
G-CSF is the main cytokine that drives granulopoie-
sis exerting its function through the G-CSF receptor 
(G-CSFR). G-CSFR is a single transmembrane receptor 
that belongs to the cytokine receptor type I superfam-
ily [10]. The intracellular region lacks intrinsic tyrosine 
kinase activity, but contains two conserved membrane-
proximal motifs: box 1 and box 2, involved in Jak kinase 
activation. In the membrane-distal intracellular tail, 
there is a more distal box 3 motif and specific tyrosine 
residues important for signaling transduction [11]. Upon 
ligand recognition, G-CSFR homodimerizes allowing 
trans-phosphorylation and activation of Jak2 kinases 
that are constantly bound to box 1 and 2, which conse-
quently initiates downstream intracellular signaling cas-
cades, including Jak/STAT/Socs, Ras/Raf/Erk and PI3K/
Akt pathways. As a result, transcription changes that 
impact on survival, migration, proliferation and differen-
tiation are induced [12]. G-CSF/G-CSFR axis regulates 
myelopoiesis under basal conditions of hematopoiesis 
and neutrophil production during emergency granu-
lopoiesis [4]. G-CSF signaling is implicated in hematopoi-
etic stem/progenitor cell mobilization through three 
different mechanisms G-CSFR-independent: induction of 
proteases, attenuation of function of adhesion molecules, 
and disruption of signaling initiated by CXCL12 (SDF-1) 
through CXCR4 [13]. G-CSF also promotes mobilization 
of mature myeloid cells via induction of the transcrip-
tional repressor GFI-1, which attenuates their responsi-
bleness to bone marrow CXCL12 [14].
Here, we analyzed the ex vivo effect of G-CSF on pri-
mary AML samples in order to elucidate the biological 
mechanisms underlying chemotherapy priming strate-
gies with this agent [15–18]. Our results suggest that 
the anti-leukemic effect of G-CSF treatment is mostly 
stroma-dependent. Moreover, cell viability and clono-
genic capacity was significantly reduced upon G-CSF 
treatment in chemosensitive AML samples. Thus, this 
correlation between pre-clinical ex  vivo observation 
and clinical results might be used to anticipate clinical 
response to chemotherapy and select optimal therapy.
Results
In order to study the effect of G-CSF on cell viability, 
bulk AML blast population was treated with increasing 
doses of G-CSF. In concordance with previous data [19], 
no significant differences were observed in cell number 
24 and 72  h after treatment (Fig.  1a, Additional file  1: 
Figure S1A). Treatment with G-CSF upregulated CXCR4 
expression in a dose-dependent fashion (Fig.  1b, Addi-
tional file  1: Figure  S1B), demonstrating that although 
G-CSF signaling was activated, no influence over cell 
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Fig. 1 G‑CSF treatment spares AML blasts while it increased surface CXCR4 expression. Primary patient AML cells were cultured in the presence 
of 0.1, 1 and 10 μg/mL of G‑CSF for 24 and 72 h. a Cell viability was measured by live‑death discrimination (7‑AAD) and volumetric count by flow 
cytometry. b CXCR4 surface expression was measured by flow cytometry. ** p < 0.01; *** p < 0.005
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viability was observed. In contrast, when bone marrow 
stroma cells were added to mimic their physiological 
niche, G-CSF treatment induced a significant reduction 
in the overall cell viability at 24  h (Fig.  2a, Additional 
file  1: Figure  S1C). Interestingly, no changes in CXCR4 
expression were observed (Fig.  2b, Additional file  1: 
Figure  S1D). The reduction of cell viability observed on 
AML cells treated with G-CSF was not due to cytotox-
icity on bone marrow stroma cells. In fact, stroma cells 
remained unaffected upon G-CSF treatment in terms of 
cytotoxicity or morphology (Fig. 2c). 
After, the requirement of a direct contact with stroma 
cells was investigated. Cell viability of the AML blast 
population remained unaffected when no direct contact 
with stroma cells was allowed by using a transwell system 
(Fig. 3a). In addition, CXCR4 expression remained unaf-
fected (Fig. 3b). These findings suggest that the cytotoxic 
effect of G-CSF on the AML blast population requires 
not only the presence of bone marrow microenvironment 
cells, but also a direct contact with stroma cells. How-
ever, taking into account the absence of changes in the 
CXCR4 levels, it is unlikely that the effect is mediated by 
the CXCR4/CXCL12 axis. In fact, G-CSF exerts its effect 
also on BM stroma cells.
The ability of G-CSF to induce differentiation and, 
eventually, sensitization of LSCs to chemotherapy may 
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Fig. 2 G‑CSF treatment significantly reduced cell viability of AML blasts in the presence of bone marrow stroma, while CXCR4 expression remained 
unaffected. Primary patient AML cells were co‑cultured with HS‑5 human bone marrow stromal cell line and treated with G‑CSF at increasing con‑
centrations for 24 h. a Cell viability was measured by live‑death discrimination (7‑AAD) and volumetric count by flow cytometry. b CXCR4 surface 
expression was measured by flow cytometry. c HS‑5 human bone marrow stromal cells were treated with G‑CSF at increasing concentrations for 
24 h. Cell viability was measured as for a. *** p < 0.005
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be relevant in a clinical setting to enhance anti-leukemic 
effect of current standard treatment [4]. Since a clo-
nogenic capacity assay in a semi-solid media remains 
the gold standard technique to study the LSC function 
ex vivo, primary AML samples were treated with G-CSF 
for 18  h and a significant reduction of CFU-B colonies 
was observed in a dose-dependent manner upon treat-
ment with G-CSF (Fig. 4a), suggesting that G-CSF exerts 
its effect at least partially on LSC function.
The beneficial effect of the concomitant use of G-CSF 
with induction chemotherapy reported in previous clini-
cal studies was mainly observed in the subset of patients 
with a cytogenetic intermediate-risk AML [20]. Thus, the 
response to G-CSF treatment ex vivo of primary AML cells 
was compared to the observed clinical patient response to 
the induction chemotherapy regimen. No differences in 
cell viability were detected both, in the presence or absence 
of stroma cells, depending on clinical response to induc-
tion treatment. In contrast, the clonogenic capacity was 
markedly reduced in samples from patients who achieved 
a first complete remission after induction treatment, com-
pared to samples from chemorefractory patients (Fig. 4b).
Discussion
As a summary, G-CSF reduced the viability of leukemic 
cells in the presence of stroma cells, highlighting the 
importance of the microenvironment for the anti-leu-
kemia effect of G-CSF. Interestingly, G-CSF treatment 
decreased the clonogenic capacity of AML samples. As 
the clonogenic assay remains the gold standard for assess-
ing LSC functionality, this finding suggests that G-CSF 
exerts its effect at least partially on LSC. It is in contrast 
with the lack of effect of G-CSF on leukemic cell viabil-
ity in the absence of stroma. However, as the frequency 
of LCS inside the AML bulk population is relatively low, 
the effect of G-CSF in this leukemic population could 
be challenging to be measured by flow cytometry. The 
observed correlation between the degree of reduction of 
clonogenic capacity of primary AML cells following expo-
sition to G-CSF and clinical response observed in the 
same patients to induction chemotherapy provide insights 
to the selective benefit in determined cytogenetic patient 
populations reported in previous clinical studies. These 
results are consistent with the previously reported data 
by the HOVON cooperative group [6], where the unfa-
vorable cytogenetic risk group of patients did not obtain 
a major clinic benefit from G-CSF priming strategy. The 
fact that AML samples from primary refractory patients 
showed a lower reduction in their clonogenic capacity 
after treatment with G-CSF supports the notion that the 
priming strategy with this agent should be more efficient 
in patients with a greater degree of chemosensitivity. 
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Fig. 3 Cell viability of the AML blast population and CXCR4 expression remained unaffected when no direct contact with stroma cells was allowed. 
Primary patient AML samples were co‑cultured with HS‑5 cells in a transwell system and treated with G‑CSF at increasing concentrations for 24 h. a 
Cell viability and b CXCR4 surface expression were measured by flow cytometry
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Therefore, ex  vivo clonogenicity assays could be used to 
predict clinical response to priming strategies, although 
further studies aimed to analyze this correlation between 
experimental and clinical results are required.
Conclusions
1. Reveals that the cytotoxic effect of G-CSF treatment 
on AML is stroma-dependent.
2. Demonstrates that the presence of G-CSF reduces 
the clonogenic capacity of AML blasts, especially in 
chemosensitive AML cells.
3. Identifies G-CSF as a priming agent in primary che-
mosensitive patients and supports further studies to 
explore new strategies of chemotherapy priming in 
AML patients.
4. Establishes a biological explanation to clinical stud-
ies, resolving the discrepancies in the field regarding 
G-CSF treatment.
Methods
Patient samples
Primary AML samples were obtained from patients 
diagnosed with AML at Hospital Clínic of Barcelona 
before receiving any treatment. Diagnoses were based 
on WHO 2008 criteria and their main characteristics 
are summarized in Table 1. All patients provided written 
informed consent in accordance with the Declaration of 
Helsinki, and the study was approved by the Ethics Com-
mittee of Hospital Clínic of Barcelona.
Cell viability assay
Five-hundred cells per ml were cultured in 96-well 
plates in complete IMDM medium (PAA). G-CSF (Pre-
poTech) was added at different concentrations. Co-
culture experiments with stromal cells were performed 
seeding 30 × 103 HS-5 cells together with 1 × 105 AML 
cells in a 96-well plate. Cell viability was measured by 
7-AAD (eBioscience) exclusion and cell count was 
obtained by volume in a FACSCanto II cytometer (BD). 
In co-culture experiments, AML cells were discrimi-
nated based on their CD45 expression (BD). For CXCR4 
determination, cells were stained on the surface with 
an anti-CXCR4 antibody (clone 12G5, BD) and samples 
were acquired in a FACSCantoII (BD). Flow cytometry 
fcs files were analyzed using FlowJo software (TriStar) 
and statistics were calculated in GraphPad (Prism soft-
ware). Each experimental point was normalized against 
the mean value corresponding to the vehicle treated 
control triplicates. A 2-tailed Mann–Whitney test was 
performed to determinate statistical significance.
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Fig. 4 G‑CSF treatment reduced the clonogenic capacity of AML bulk population. Primary patient AML samples were treated with G‑CSF as 
indicated for 18 h. a CFU‑B were counted based on morphological criteria. b Relative change in the clonogenic capacity after G‑CSF treatment in 
patients who achieved a complete response after induction treatment (CS) compared to primary chemorefractory patients (CR). Each symbol cor‑
responds to an AML patient. All data was normalized against control. *p < 0.05, **p < 0.01, ***p < 0.001
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Transwell assay
Membranes with 1  μm pore size (Falcon) were used in 
a 24-wells format. A total of 100,000 HS-5 cells were 
added to the lower compartment. 300,000 primary AML 
patient samples were added to the upper compartment. 
Both compartments were filled with complete media as 
described above. Cells were incubated 24 h and analyzed 
as for viability assays.
CFU assay
AML primary samples were treated for 18 h with G-CSF 
(PrepoTech) at different concentrations in complete 
IMDM medium and cultured in MethoCult H4034 
(StemCell Technologies) for 14  days. Colonies were 
counted based on cellularity and morphology criteria.
Additional file
Additional file 1: Figure S1. G‑CSF treatment significantly reduced cell 
viability of AML blasts in the presence of bone marrow stroma. Primary patient 
AML cells were cultured in the presence of 0.1, 1 and 10 μg/mL of G‑CSF 
for 24 and 72 h. (A) Cell viability was measured by live‑death discrimination 
(7‑AAD) and volumetric count by flow cytometry. (B) CXCR4 surface expres‑
sion was measured by flow cytometry. The same primary patient AML sample 
set was co‑cultured with HS‑5 human bone marrow stromal cell line and 
treated with G‑CSF at increasing concentrations for 24 h. (C) Cell viability was 
measured by live‑death discrimination (7‑AAD) and volumetric count by flow 
cytometry. (D) CXCR4 surface expression was measured by flow cytometry.
Table 1 AML patients’ characteristics
M male, F female, yo years old, FLT3-ITD FLT3 internal tandem duplication, CEBPAmut biallelic CEBPA mutation, FLT3 ITDneg absence of FLT3-ITD, NPM1wt wild-type NPM1, 
NPM1mut mutated NPM1, Wt wildtype
AML sample Gender Age (yo) WHO 2008 category Karyotype NPM1,FLT3-ITD, CEBPA 
and DNMT3A mutational 
status
Chemosensitivity
#1 M 28 AML NOS, without matura‑
tion
46, XY FLT3 ITD CS
#2 M 40 AML with mutated CEBPA 46, XY CEBPAmut
#3 F 34 AML with myelodysplasia‑
related changes
45, XX, −7 FLT3 ITDneg, NPM1wt CR
#4 M 45 AML with t(6,9)(p23;q34);DEK‑
NUP214
46, XY, t(6;9)(p23;q34) FLT3 ITD CS
#6 M 61 AML with t(8;21)(q22;q22); 
RUNX1‑RUNX1T1
45, X–Y, t(8;21)(q22;q22)
[19]/46, XY
FLT3 ITDneg, NPM1wt CS
#7 F 58 AML with myelodysplasia‑
related changes
46, XX, del(5)(q23q33), t(8;9)
(p11;q34)
FLT3 ITDneg, NPM1wt
#8 M 24 AML with myelodysplasia‑
related changes
46, XY FLT3 ITDneg, NPM1wt
#9 M 49 AML with myelodysplasia‑
related changes
Complex karyotype FLT3 ITDneg, NPM1wt
#10 F 66 AML with myelodysplasia‑
related changes
46, XX, del(11)(q22q23) FLT3 ITD
#11 M 22 AML with t(8;21)(q22;q22); 
RUNX1‑RUNX1T1
45, X, −Y, t(8;21)(q22;q22)/46, 
XY
FLT3 ITD CS
#12 F 22 AML with inv(16)
(p13.1q22);CBFB‑MYH11
46, XX, inv(16)(p13q22)/46, XX FLT3 ITDneg, NPM1wt
#13 M 37 AML with mutated NPM1 46, XY NPM1mut, DNMT3Amut
#14 M 42 AML with mutated NPM1 46, XY NPM1mut, FLT3 ITD
#15 F 60 AML with myelodysplasia‑
related changes
48, XX, +8, +21 FLT3 ITDneg, NPM1wt
#16 F 62 AML NOS, with maturation 46, XX FLT3 ITDneg, NPM1wt
#17 F 60 AML with myelodysplasia‑
related changes
Complex karyotype FLT3 ITDneg, NPM1wt
#18 F 55 AML with inv(16)
(p13.1q22);CBFB‑MYH11
46, XX, inv(16)(p13q22)/46, XX FLT3 ITDneg, NPM1wt
#19 M 63 AML with myelodysplasia‑
related changes
46, XY FLT3 ITD CR
#20 M 61 AML with mutated NPM1 46, XY NPM1mut, DNMT3Amut CR
#21 F 51 AML NOS, acute monoblastic 
leukemia
Not available NPM1mut, FLT3 ITDneg
#22 F 36 AML with mutated NPM1 46, XX NPM1mut, FLT3 ITDneg
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